Medical aesthetic laser device developer Lumenis (OTCBB:LUME) announced today that it has received FDA clearance to market the new Novus 3000 ophthalmic treatment device. The Novus 3000 is a 532 nm diode-pumped solid-state (DPSS) photocoagulator. Its predecessor system, the Lumenis' Novus 2000 had approximately 1,500 units installed. Lumenis specifically designed the Novus 3000 to improve upon this strong performance.
Lumenis president and CEO Avner Raz said, "Lumenis has provided the ophthalmic industry with innovative technology since 1970, when we introduced the world's 'first' laser photocoagulator. These lasers treat several retinal conditions that can lead to vision loss and blindness, and include conditions such as proliferative diabetic retinopathy, retinopathy of prematurity, retinal tears and detachment and retinal vein occlusion.
"Worldwide, estimates suggest over 30 million people suffer from these conditions, and as the population ages these numbers are expected to climb. With the addition of our Novus 3000, we once again demonstrate our commitment to helping patients and their ophthalmologists protect and preserve sight."
Lumenis also received FDA clearance to market the Coaxial Multicolor LIO, for the delivery of photocoagulator laser energy during ophthalmic surgery.
Published by Globes [online], Israel business news - www.globes.co.il - on Tuesday, November 29, 2005